Immunotherapy for EGFR-mutant Advanced Non-small-cell Lung Cancer: Current Status, Possible Mechanisms and Application Prospects

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 8

PMID 35935943

Authors

Chunyan Shi

Yan Wang

Jianxin Xue

Xiaojuan Zhou

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) are effective against advanced and even perioperative non-small-cell lung cancer (NSCLC) and result in durable clinical benefit, regardless of programmed death ligand-1 (PD-L1) expression status in cancer. Existing clinical evidence shows that the effect of immunotherapy in patients with EGFR-mutant NSCLC after the development of tyrosine kinase inhibitor (TKI) resistance is not satisfactory. However, compared with monotherapy, ICIs combined with chemotherapy can improve the efficacy. Encouragingly, compared with that of patients with sensitive mutations, the progression-free survival of patients with rare mutations who were treated with ICIs was increased. Adequately maximizing the efficacy of ICIs in EGFR-mutant NSCLC patients is worth exploring. In this review, we described preclinical and clinical studies of ICIs or combined therapy for EGFR-mutant NSCLC. We further focused on EGFR mutations and the cancer immune response, with particular attention given to the role of EGFR activation in the cancer-immunity cycle. The mechanisms for the natural resistance to ICIs were explored to identify corresponding countermeasures that made more EGFR-mutant NSCLC patients benefit from ICIs.

Citing Articles

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review.

Dong Y, Khan L, Yao Y J Natl Cancer Cent. 2024; 4(4):289-298.

PMID: 39735443 PMC: 11674437. DOI: 10.1016/j.jncc.2024.06.004.

Identifying biomarkers to predict immune-checkpoint therapy response-is it a reality or a distant dream?.

Ashok Kumar P Transl Cancer Res. 2024; 13(11):6590-6593.

PMID: 39697699 PMC: 11651762. DOI: 10.21037/tcr-24-1383.

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations.

Thomas B, Awan S, Joshi T, Daniels M, Porciani D, Burke D NPJ Precis Oncol. 2024; 8(1):271.

PMID: 39572699 PMC: 11582725. DOI: 10.1038/s41698-024-00758-9.

BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.

Lim S, Schalm S, Lee E, Park S, Conti C, Millet Y Ther Adv Med Oncol. 2024; 16:17588359241280689.

PMID: 39444426 PMC: 11497503. DOI: 10.1177/17588359241280689.

Non-small-cell lung cancer.

Hendriks L, Remon J, Faivre-Finn C, Garassino M, Heymach J, Kerr K Nat Rev Dis Primers. 2024; 10(1):71.

PMID: 39327441 DOI: 10.1038/s41572-024-00551-9.

References

Kamphorst A, Wieland A, Nasti T, Yang S, Zhang R, Barber D . Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017; 355(6332):1423-1427. PMC: 5595217. DOI: 10.1126/science.aaf0683. View

Gubens M, Sequist L, Stevenson J, Powell S, Villaruz L, Gadgeel S . Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 2019; 130:59-66. DOI: 10.1016/j.lungcan.2018.12.015. View

Young A, Mittal D, Stagg J, Smyth M . Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014; 4(8):879-88. DOI: 10.1158/2159-8290.CD-14-0341. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Golden E, Pellicciotta I, Demaria S, Barcellos-Hoff M, Formenti S . The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol. 2012; 2:88. PMC: 3413017. DOI: 10.3389/fonc.2012.00088. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Nilsson M, Robichaux J, Herynk M, Cascone T, Le X, Elamin Y . Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol. 2020; 16(3):439-451. PMC: 8207565. DOI: 10.1016/j.jtho.2020.11.022. View

10.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

11.

Sharonov G, Serebrovskaya E, Yuzhakova D, Britanova O, Chudakov D . B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat Rev Immunol. 2020; 20(5):294-307. DOI: 10.1038/s41577-019-0257-x. View

12.

Zhang M, Nie L, Cheng Y . Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report. Thorac Cancer. 2021; 12(20):2803-2806. PMC: 8520811. DOI: 10.1111/1759-7714.14101. View

13.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

14.

Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016; 14(3):255-64. PMC: 10181272. DOI: 10.6004/jnccn.2016.0031. View

15.

Miyawaki E, Murakami H, Mori K, Mamesaya N, Kawamura T, Kobayashi H . PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. Jpn J Clin Oncol. 2020; 50(5):617-622. DOI: 10.1093/jjco/hyaa033. View

16.

Lam T, Tsang K, Choi H, Lee V, Lam K, Chiang C . Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure. Lung Cancer. 2021; 159:18-26. DOI: 10.1016/j.lungcan.2021.07.004. View

17.

Yang J, Gadgeel S, Sequist L, Wu C, Papadimitrakopoulou V, Su W . Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2018; 14(3):553-559. DOI: 10.1016/j.jtho.2018.11.028. View

18.

Ferguson T, Choi J, Green D . Armed response: how dying cells influence T-cell functions. Immunol Rev. 2011; 241(1):77-88. PMC: 3097899. DOI: 10.1111/j.1600-065X.2011.01006.x. View

19.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

20.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View